Candel Therapeutics Income Statement (2020-2025) | CADL

Income Statement Jun2020 Sep2020 Dec2020 Mar2021 Jun2021 Sep2021 Dec2021 Mar2022 Jun2022 Sep2022 Dec2022 Mar2023 Jun2023 Sep2023 Dec2023 Mar2024 Jun2024 Sep2024 Dec2024 Mar2025 Jun2025 Sep2025 Dec2025
Revenue & cost
Revenue (Quarter)
0.03M0.03M0.03M0.01M0.03M0.03M0.03M0.03M
Operating items
Research & Development (Quarter)
2.75M3.29M5.26M3.85M5.42M5.02M5.38M4.97M5.47M5.93M5.84M7.26M4.10M0.92M5.42M4.82M1.25M6.99M3.85M6.59M
Wages, Salaries and Other (Quarter)
1.64M1.21M1.68M1.19M1.72M1.95M1.21M3.18M
Selling, General & Administrative (Quarter)
1.94M2.04M2.79M3.92M3.60M3.76M3.54M3.16M4.16M3.65M3.02M3.06M3.80M3.59M3.34M3.32M4.11M4.19M4.75M4.72M
Restructuring Costs (Quarter)
0.49M0.52M0.46M0.49M0.46M0.46M0.44M0.48M
Other Operating Expenses (Quarter)
-0.49M3.54M-0.46M-0.49M2.31M-0.46M4.17M3.95M
Operating Expenses (Quarter)
4.69M5.33M8.06M7.77M9.02M8.78M8.91M8.13M9.63M9.58M8.86M10.32M7.90M8.57M8.76M8.14M8.13M11.18M13.21M15.75M
Operating Income (Quarter)
-4.66M-5.30M-8.03M-7.74M-8.99M-8.75M-8.88M-8.10M-9.63M-9.58M-8.86M-10.32M-7.90M-8.57M-8.76M-8.14M-8.13M-11.18M-13.21M-15.75M
EBIT (Quarter)
-4.66M-5.30M-8.03M-7.74M-8.99M-8.75M-8.88M-8.10M-9.63M-9.58M-8.86M-10.32M-7.90M-8.57M-8.76M-8.14M-8.13M-11.18M-13.21M-15.75M
Non-operating items
Interest & Investment Income (Quarter)
-0.01M-0.01M-0.01M-0.01M-0.17M0.07M0.34M0.80M0.71M0.45M0.50M0.41M0.32M0.24M0.24M0.29M0.93M0.93M0.95M1.10M
Non Operating Income (Quarter)
0.18M-11.78M0.13M9.34M8.11M4.60M0.19M3.02M0.01M-0.04M0.43M-0.78M-0.32M-13.67M-1.89M-5.93M15.51M6.38M1.94M-23.74M
Net income details
EBT (Quarter)
-4.67M-5.32M-8.04M-7.75M-9.16M-9.12M-9.06M-7.88M-9.53M-9.77M-9.03M-10.58M-8.23M-8.90M-9.01M-8.24M-7.50M-10.49M-12.41M-16.07M
Profit After Tax (Quarter)
-4.48M-17.08M-16.16M1.60M-0.90M-4.15M-8.69M-5.08M-8.79M-9.61M-8.44M-11.10M-8.20M-22.24M-10.65M-14.10M7.38M-4.80M-11.27M-29.48M
Income from Continuing Operations (Quarter)
-4.67M-5.32M-8.04M-7.75M-9.16M-9.12M-9.06M-7.88M-9.53M-9.77M-9.03M-10.58M-8.23M-8.90M-9.01M-8.24M-7.50M-10.49M-12.41M-16.07M
Consolidated Net Income (Quarter)
-4.67M-5.32M-8.04M-7.75M-9.16M-9.12M-9.06M-7.88M-9.53M-9.77M-9.03M-10.58M-8.23M-8.90M-9.01M-8.24M-7.50M-10.49M-12.41M-16.07M
Income towards Parent Company (Quarter)
-4.67M-5.32M-8.04M-7.75M-9.16M-9.12M-9.06M-7.88M-9.53M-9.77M-9.03M-10.58M-8.23M-8.90M-9.01M-8.24M-7.50M-10.49M-12.41M-16.07M
Net Income towards Common Stockholders (Quarter)
-4.67M-5.32M-8.04M-7.75M-9.16M-9.12M-9.06M-7.88M-9.53M-9.77M-9.03M-10.58M-8.23M-8.90M-9.01M-8.24M-7.50M-10.49M-12.41M-16.07M
Additional items
EPS (Basic) (Quarter)
-0.38-1.46-0.690.51-0.03-0.14-0.30-0.17-0.30-0.33-0.29-0.38-0.28-0.74-0.33-0.390.15-0.09-0.21-0.55
EPS (Weighted Average and Diluted) (Quarter)
-1.46-0.690.51-0.03-0.14-0.30-0.17-0.30-0.33-0.29-0.38-0.28-0.74-0.33-0.390.13-0.09-0.21-0.55
Shares Outstanding (Weighted Average) (Quarter)
11.65M11.68M23.33M18.87M28.69M28.75M28.80M28.82M28.92M28.92M28.92M28.94M29.20M29.54M30.37M31.68M50.48M50.99M54.89M52.96M
Shares Outstanding (Diluted Average) (Quarter)
11.72M23.33M18.87M28.69M28.81M28.80M28.82M28.92M28.92M28.92M28.94M29.20M29.54M32.01M31.68M52.96M
EBITDA (Quarter)
-4.66M-17.08M-16.16M1.60M-8.99M-8.75M-8.88M-8.10M-9.63M-9.58M-8.86M-10.32M-7.90M-8.57M-8.76M-8.14M-8.13M-11.18M-13.21M-15.75M
Interest Expenses (Quarter)
0.43M0.52M0.58M0.61M0.64M0.67M0.67M0.65M0.57M0.49M0.39M0.31M0.24M0.16M1.42M
Shares Outstanding (Quarter)
11.67M11.73M28.69M28.69M28.69M29.01M-0.12M-0.12M-0.12M29.04M29.04M29.21M29.47M31.19M32.25M46.81M49.37M55.01M55.02M54.90M